CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


QuestionnaireWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (33)


Name (Synonyms) Correlation
drug2183 Saline solution Wiki 0.29
drug185 Anti-SARS-CoV2 Serology Wiki 0.29
drug992 Gas exchanges at different PEEP Wiki 0.21
drug1920 Prone decubitus Wiki 0.21
drug724 Data collection up to 1 year Wiki 0.21
drug2846 hyperbaric oxygen therapy (HBOT) Wiki 0.21
drug1430 Mannitol Wiki 0.21
drug1720 Oxygen-ozone therapy, probiotic supplementation and Standard of care Wiki 0.21
drug2397 Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors Wiki 0.21
drug1046 Hemodynamics changes at different PEEP Wiki 0.21
drug2303 Standard Donor Plasma Wiki 0.21
drug2222 Selitrectinib (BAY2731954) Wiki 0.21
drug2875 lung mechanics at different PEEP Wiki 0.21
drug645 Convalescent COVID 19 Plasma Wiki 0.21
drug186 Anti-SARS-CoV2 serological controls and serum neutralization Wiki 0.21
drug1169 IgG Wiki 0.21
drug1910 Probiorinse Wiki 0.21
drug218 Aspirin 100mg Wiki 0.21
drug2244 Serum test Wiki 0.21
drug2534 Tocilizumab Injection Wiki 0.15
drug1376 Low Dose Radiation Therapy Wiki 0.15
drug2235 Serological test Wiki 0.15
drug733 Deferoxamine Wiki 0.15
drug2271 SivoMixx (200 billion) Wiki 0.15
drug1220 Interferon Beta-1B Wiki 0.12
drug1243 Interview Wiki 0.12
drug1219 Interferon Beta-1A Wiki 0.10
drug2840 hydroxychloroquine Wiki 0.10
drug1355 Lopinavir / Ritonavir Wiki 0.10
drug647 Convalescent Plasma Wiki 0.09
drug1086 Hydroxychloroquine Wiki 0.08
drug262 Azithromycin Wiki 0.04
drug1822 Placebo Wiki 0.01

Correlated MeSH Terms (23)


Name (Synonyms) Correlation
D002386 Cataract NIH 0.21
D012170 Retinal Vein Occlusion NIH 0.21
D005157 Facial Pain NIH 0.21
D007246 Infertility NIH 0.19
D002055 Burnout, Professional NIH 0.19
D008268 Macular Degeneration NIH 0.15
D008269 Macular Edema NIH 0.15
D000077062 Burnout, Psychological NIH 0.13
D003550 Cystic Fibrosis NIH 0.12
D018352 Coronavirus Infections NIH 0.09
D005355 Fibrosis NIH 0.09
D007153 Immunologic Deficiency Syndromes NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.08
D007239 Infection NIH 0.06
D003141 Communicable Diseases NIH 0.05
D055371 Acute Lung Injury NIH 0.04
D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
D004630 Emergencies NIH 0.04
D011014 Pneumonia NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D003863 Depression, NIH 0.03
D011024 Pneumonia, Viral NIH 0.03
D013577 Syndrome NIH 0.02

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0000518 Cataract HPO 0.21
HP:0012636 Retinal vein occlusion HPO 0.21
HP:0000789 Infertility HPO 0.19
HP:0011505 Cystoid macular edema HPO 0.15
HP:0002721 Immunodeficiency HPO 0.09
HP:0002090 Pneumonia HPO 0.04

There are 23 clinical trials

Clinical Trials


1 Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence

Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening

NCT04334252 COVID 19 Other: Questionnaire

Primary Outcomes

Description: Prevalence of fever, cough, anorexia, fatigue, diarrhea, vomiting, dyspnee, sore throat and sputum

Measure: Prevalence of symptoms

Time: at the ambulant screening

Description: Prevalence of positive COVID 19 tests in patients planned for surgery, treatment or investigation in the hospital

Measure: Prevalence of positive Sars CoV-2 PCR

Time: at the ambulant screening

Description: Prevalence of positive radiological findings in CT scans of the lungs of planned for surgery, treatment or investigation in the hospital

Measure: Prevalence of positive radiological findings

Time: at the ambulant screening

Secondary Outcomes

Description: Prediction of symptoms of COVID 19, based on evaluated baseline questionnaire

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

Description: Prediction of symptoms of COVID 19, based on radiological findings of CT scans

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

Description: Prediction of symptoms of COVID 19, based on COVID 19 PCR results

Measure: Prediction of symptoms

Time: 2 weeks after surgery or treatment

2 COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?

A pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. The spread and severity of the disease is variable from one country to another. Our team as well as many reports suggested that in some countries a " Flu like illness but much worse" was described in October, November and early in December before the WHO announcement. Was it COVID-19?

NCT04336657 COVID-19 Other: Questionnaire Diagnostic Test: IgG

Primary Outcomes

Description: fever, dry cough, dyspnea, malaise, headache

Measure: Measure frequency of people suffered from unusual flu-like symptoms before December 2019

Time: one month

Secondary Outcomes

Description: serum IgG

Measure: Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible

Time: 3 month

3 Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period

The outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation of a specific channel for COVID-19 suspect patients. Thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...The major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. This exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. Resilience is defined as an ability to recover from or adjust easily to misfortune or change. The Resi-CoV study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.

NCT04349163 Psychological Other: Questionnaire

Primary Outcomes

Description: CD-RISC-25 : Connor-Davidson Resilience Scale - 25. This scale contain 25 questions each range from 1 to 5. The total is 100 points which means a very high level of resilience.

Measure: compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.

Time: 14 days

4 Evaluation of the Management of Dental Emergencies During COVID 19 Crisis

"For 12 years, the odontology service of the Pitié-Salpêtrière hospital group (GHPS) has been responsible for day and night dental emergency care. Several surveys have been conducted in order to analyze the sociological characteristics of the patients and the typology of the acts performed. These studies indicate that pain is the main reason for consultations, cited by 60 to 80% of patients. So far, very few studies have been done in the context of emergencies. Very recently, a study was undertaken on the satisfaction of patients consulting the odontological emergencies of the GHPS, during a thesis work. This study, carried out in collaboration with the URC Pitié Salpêtrière, under analysis, relates to the satisfaction of patients consulting the odontological emergencies of the GHPS during the day and week, Monday to Friday, excluding night and week emergencies -end (WE). An additional study (URGDENT-NW) aiming at completing this study by focusing on patients consulting the emergency room at night and during the weekend is also in progress. The COVID19 Crisis changed the organization and the venue of patients at the emergency dental service. Therefore this project, based on the same protocol as URGENT and URGDENT-WE, aims at evaluating the Odontology Emergency Reception Service (SAUO) during the COVID 19 epidemy. It will be carried out in the form of a survey whose objective is to assess: on the one hand, the effectiveness of the care provided in this emergency functional unit, and on the other hand the satisfaction of the patients after their passage to the emergency room ."

NCT04354272 Orofacial Pain Orofacial Edema Dental Trauma Oral Infection Other: Questionnaire
MeSH:Emergencies Facial Pain

Primary Outcomes

Description: "Self report measure of pain on the numeric scale 24h after the visit "

Measure: Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable

Time: Day 1

Secondary Outcomes

Description: the pain is measured with the numeric scale

Measure: Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable

Time: Day 3 and Day 7

Description: Perception of welcoming, waiting time will be measured with a 0-10 numeric scale

Measure: welcoming quality from hospital staff

Time: Day 1

Description: The patient anxiety will be measured by numeric scale at Day 0, Day 1, Day 3, Day 7

Measure: anxiety score

Time: Day 0, Day 1, Day 3, Day 7

Description: The perception is measured just after care with a 0-10 numeric scale

Measure: perception of the technical quality of the emergency treatment

Time: Day 1

5 Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers

This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization. It will also provide a record of the progress of patients who will have been treated during the epidemic period and infected by the virus. We will also assess the psychological impact of the pandemic in patients but also in caregivers

NCT04366154 COVID-19 Cancer Other: Questionnaire
MeSH:Communicable Diseases Infection

Primary Outcomes

Description: Proportion of patients with modification of the treatments administered

Measure: To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change in the rate of treatment administration

Measure: To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change in the number of cures administered

Measure: To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Description: Proportion of patients with change of modality of administration (home administration to replace day hospital administration, teleconsultation uses)

Measure: To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy

Time: up to 6 months

Secondary Outcomes

Description: Score of questionnaires of Perceived Stress Scale [0-40 points]

Measure: Evaluate the perceived stress on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]

Measure: Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of sleep disorders (ISI scale, 0-28 points)

Measure: Evaluate the sleep disorders on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of quality of life (FACT-G scale)

Measure: Evaluate the quality of life on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of cognitive complaints (Fact-Cog scales; 0-148 points)

Measure: Evaluate the cognitive complaints on cancer patients treated in unit day of hospital

Time: up to 6 months

Description: Score of questionnaires of Perceived Stress Scale [0-40 points]

Measure: Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]

Measure: Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of burnout ((Maslach Burn Out Inventory scale, 0-132 points)

Measure: Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

Description: Score of questionnaires of feeling of personal effectiveness (0-30 points)

Measure: Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)

Time: up to 3 months

6 Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit of an Exclusively Covid-19 Hospital: the Malaysian Experience

The investigators plan to perform an observational study to evaluate the prevalence of burnout, depression and medical errors in a designated exclusive Covid-19 patients hospital in Malaysia, during the Covid-19 pandemic. In addition, the relationship between burnout and depression with medical errors will be assessed. The population studied will be the nurses working in the Intensive Care Unit, who are at higher risk due to the nature of their work at the frontlines of the pandemic.

NCT04371302 Burnout, Professional Medical Errors Depression Diagnostic Test: Questionnaire
MeSH:Burnout, Professional Depression Burnout, Psychological

Primary Outcomes

Description: Prevalence of burnout risk

Measure: Prevalence of burnout among ICU nurses during Covid-19

Time: 2 months

Description: Prevalence of depression risk

Measure: Prevalence of depression among ICU nurses during Covid-19

Time: 2 months

Description: Prevalence of self perceived medical errors

Measure: Prevalence of self-perceived medical errors among ICU nurses during Covid-19

Time: 2 months

Description: To find out if there exists a relationship between burnout, depression and medical errors

Measure: Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19

Time: 2 months

7 Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.

The term "sleep hygiene" refers to a series of healthy sleep habits that can improve the ability to fall asleep. These habits are the most effective long-term treatment for people with chronic insomnia. The "Sleep Hygiene Index" is a 13-item questionnaire that evaluates these habits. We are in the process of validation of this questionnaire in the arabic language. We will evaluate these habits in the Lebanese population during the COVID-19 confinement period.

NCT04372043 Sleep Hygiene Other: Questionnaire

Primary Outcomes

Measure: Sleep Hygiene

Time: 30/04/2020 to 30/12/2020

8 Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.

A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.

NCT04382508 Immune Suppression Immune Deficiency Infection COVID Children, Adult Other: Questionnaire
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Immunologic Deficiency Syndromes
HPO:Immunodeficiency

Primary Outcomes

Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year

Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting

Time: 1 year

Secondary Outcomes

Description: Patient/parent reported positive tests for COVID19

Measure: Number of children/adults tested positive for COVID19

Time: 1 year

Description: Patient/parent reported admissions in hospital because of COVID19

Measure: Number of children/adults admitted in hospital because of COVID19

Time: 1 year

Description: Patient/parent reported effect of COVID19 on daily activities

Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children

Time: 1 year

9 Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019 (COVID-19) Infections: a Case-control Study

It has been suggested that ibuprofen might be associated with more severe cases of coronavirus infections, based on the observation that severe COVID cases had been exposed to ibuprofen, resulting in a warning by the French authorities. This was attributed to: 1. a suggestion that ibuprofen might upregulate ACE-2 thereby increasing the entrance of COVID-19 into the cells, 2. an analogy with bacterial soft-tissue infections where more severe infections on NSAIDs are attributed to an immune-depressive action of NSAIDs, or to belated treatment because of initial symptom suppression, 3. fever is a natural response to viral infection, and reduces virus activity: antipyretic activity might reduce natural defenses against viruses. However fever reduction in critically ill patients had no effect on survival. However, these assertions are unclear: upregulation of ACEII would increase the risk of infection, not necessarily its severity, and would only apply to the use of NSAIDs before the infection, i.e. chronic exposure. It would be irrelevant to the infection once the patients are infected, i.e., to symptomatic treatment of COVID-19 infection. Anti-inflammatory effect masking the early symptoms of bacterial infections resulting in later antibiotic or other treatment is not applicable: there is no treatment of the virus that might be affected by masking symptoms. Antipyretic effect increasing the risk or the severity of infection would apply equally to all antipyretic agents including paracetamol, which share the same mechanism of action for fever reduction. EMA remains prudent about this assertion In addition, excess reliance on paracetamol while discouraging the use of ibuprofen might increase the risk of hepatic injury from paracetamol overdose. Paracetamol is the prime drug associated with liver injury and transplantation, in voluntary and inadvertent overdose or even at normal doses. This might be increased by COVID-related liver function alterations. It is therefore proposed to conduct a case-control study in a cohort of patients admitted to hospital in France with COVID-19 infection.

NCT04383899 Coronavirus Infection Other: Questionnaire
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Synd Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Describe medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions on existing pathology, drugs administrated symptom onset and when, hospitalisation. Each questions have a multiple choice.

Measure: Describe medications used prior to admission associated with worse infection in COVID-19 patients in France.

Time: At inclusion day

Description: Quantify medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions: existing pathology, drugs administrated symptoms onset and when, hospitalisation. Each questions have a multiple choice.

Measure: Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France.

Time: At inclusion day

Secondary Outcomes

Description: Describe patient characteristics thanks to the same questionnaire.

Measure: Describe other patient characteristics with worse infection in COVID-19 patients in France.

Time: At inclusion day

Description: Quantify patient characteristics thanks to the same questionnaire.

Measure: Quantify other patient characteristics with worse infection in COVID-19 patients in France.

Time: At inclusion day

10 Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

NCT04387838 Sars-CoV2 Diagnostic Test: Anti-SARS-CoV2 Serology Other: Questionnaire

Primary Outcomes

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.

Time: From Day 0 to Day 60

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.

Time: From Day 0 to Day 30

Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.

Time: From Day 30 to Day 60

Secondary Outcomes

Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.

Measure: Anti-SARS-Cov2 seroprevalence at Day 0.

Time: Day 0

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex

Measure: Correlation between seroconversion and socio-demographic factors - sex

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age

Measure: Correlation between seroconversion and socio-demographic factors - age

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)

Measure: Correlation between seroconversion and professional factors - job type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type

Measure: Correlation between seroconversion and professional factors - personal protective equipment type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals

Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment

Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures

Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures

Time: Day 60

11 Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

NCT04395859 Age Related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Procedure: Questionnaire Other: Data collection up to 1 year
MeSH:Macular Degeneration Macular Edema Retinal Vein Occlusion
HPO:Cystoid macular edema Macular edema Retinal vein occlusion

Primary Outcomes

Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up

Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic

Time: Baseline (Before confinement) and 6 months after resumption of follow-up

12 Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic

The COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.

NCT04396210 Coronavirus COVID ART Fertility Issues Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Measure: Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients reproductive behaviour by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients views on resuming fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

13 Cross-sectional Descriptive Study: Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic

Doctors are at high risk of corona virus infection (COVID-19) during pandemic. The investigators are aiming to explore the emotions, perceived stressors, knowledge and coping strategies of doctors who are working during COVID-19 pandemic in different specialties and in different hospitals by a self assessment questionnaire that was designed and modified from two previously published articles (mentioned in the references), including 7 sections with 88 questions.

NCT04403581 Covid-19 Other: Questionnaire

Primary Outcomes

Description: Highlighting the emotional aspects, perceived stressors, level of knowledge and coping strategies of doctors who are working during COVID-19 pandemic in different hospitals by using questionnaires that the investigators gave the name "COVID-19 Doctor Stress Questionnaire" that included 7 sections with 88 questions: Demographic data related questions Doctors feelings related questions Factors that help in stressing doctors Factors help in reducing stresses Questions detecting knowledge Attitude towards stresses Motives to complete work Each is answered by the participant and assessed

Measure: Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic

Time: 2 months

14 Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)

In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.

NCT04404270 Sars-CoV2 Diagnostic Test: Anti-SARS-CoV2 Serology Behavioral: Questionnaire Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization

Primary Outcomes

Description: The percentage of the study population with positive serological status will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0

Measure: Proportion anti-SARS-CoV2 seropositive

Time: Day 0

Secondary Outcomes

Description: Among anti-SARS-CoV2 seropositive participants, the percentage of asymptomatic participants will be determined. COVID-19 symptoms will be measured using a questionnaire.

Measure: Proportion of asymptomatic anti-SARS-CoV2 seropositive participants

Time: Day 0

Description: The serological results obtained using the reference ELISA test results (detecting the presence of IgG and IgM antobodies) and using a second ELISA test detecting the presence of antibodies specifically directed against the Receptor Binding Domain and the Spike protein trimer of SARS-CoV2 virus will be compared.

Measure: Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies)

Time: Day 0

Description: Among anti-SARS-CoV2 seropositive participants, the percentage of participants with a positive response to serum neutralization will be determined.

Measure: Proportion of serum neutralization positive

Time: Day 0

Description: The evolution of the antibody level over time will be determined using repeated serodiagnoses at 3 and 9 months.

Measure: Change of antibody level over time

Time: 3 months and 9 months after Day 0

15 Psychological Impact of the Health Measures Generated by the SarsCov-2 Pandemic in Adolescents (COVADO)

The lockdown of the French population is a health measure put in place in response to the pandemic linked to a new coronavirus, SARS-CoV-2 (Covid-19). After a health campaign to recommend hygienic "barrier gestures" and social distancing, the decision to confine the population at the national level was decided by the executive from Monday 16 March to Monday 11 May 2020. The national confinement implies the restriction of movement to the strict necessary, outings near the home and the closure of schools and communities. These decisions have led to an unprecedented state of stress for the entire French population, the consequences of which are unknown in the short, medium or long term. The objectives of this study are to evaluate the psychological impact of the confinement on adolescents with or without chronic disease and also the difficulties and fears engendered by deconfinement .

NCT04406558 Psychological Adaptation Psychology, Social Other: Questionnaire

Primary Outcomes

Description: Scale 0-21

Measure: Anxiety score from the Generalized Anxiety Disorder 7 (GAD-7) questionnaire

Time: At inclusion

Secondary Outcomes

Description: Scale 0-60

Measure: Depression score from the Adolescent Depression Rating Scale (ADRS) questionnaire

Time: At inclusion

Description: 8 items that are scored on a four-point scale and 3 sub scales: intrusion (4 items); avoidance (4 items) and arousal (5 items)

Measure: Post traumatic score questionnaire: Children's Revised Impact of Events Scales -CRIES13

Time: At inclusion

Description: a question on the quality and quantity of sleep will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulty in falling asleep, sleeping

Time: At inclusion

Description: a question on the presence or absence of feeding difficulty will be asked to the teenager on a questionnaire

Measure: Presence or absence of feeding difficulty

Time: At inclusion

Description: a question on the presence or absence of difficulty performing physical activity will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulty performing physical activity

Time: At inclusion

Description: a question on the presence or absence of toxic consomption will be asked to the teenager on a questionnaire

Measure: Presence or absence of toxic consomption (drug, acohol) during the lockdown

Time: At inclusion

Measure: Mean duration time in front of screen (hours per day)

Time: At inclusion

Description: A question on the presence or absence of difficulties with social interactions will be asked to the teenager on a questionnaire

Measure: Presence or absence of difficulties with social interactions

Time: At inclusion

Description: Presence or absence of difficulties with familial interactions

Measure: Presence or absence of difficulties with familial interactions

Time: At inclusion

16 The Reliability, Validity and Cross-Cultural Adaptation of the Turkish Version of Jefferson Scale of Empathy For Health Professional Students

Empathy, which can be briefly defined as understanding and feeling of one's thoughts upon experiences. It has been gaining importance in health care. A great majority of the literature has been focusing on the aspect of physician and health care provider yet recently establishing or measuring empathy has been performed with the undergraduate students. Since empathy and its related dimensions are important to integrate a better skill to provide in health care, measuring empathy gained attention. However, there might be lacking some tools which assess empathy directly such as the Empathic Tendency Scale and the Empathic Skill Scale in the Turkish language, yet these were discussed as cannot be quite modifiable to some specific sub-groups such as health sciences students. Thus, this study is aimed to study for the reliability, validity, and cross-cultural adaptation of the Turkish version of the Jefferson Scale of Empathy for undergraduate health care students.

NCT04422834 Surveys and Questionnaires Empathy Other: Questionnaire

Primary Outcomes

Description: The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.

Measure: Jefferson Scale of Empathy Health Professional Students Questionnaire

Time: Baseline

Description: The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.

Measure: Jefferson Scale of Empathy Health Professional Students Questionnaire

Time: 1 week after baseline

Description: The Turkish version of Empathic Tendency Scale (ETS) Questionnaire will be applied to participants. The minimum and maximum scores can be taken from the tool are 20 and 100, respectively in which higher scores indicate better empathic attitude or vice versa.

Measure: Empathic Tendency Scale (ETS) Questionnaire

Time: Baseline

Secondary Outcomes

Description: Basic Form gathers some information related participants' age, gender etc.

Measure: Demographic Data Form

Time: Baseline

17 COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction

This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous. The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice.

NCT04433286 Physical Stress Career Burnout Satisfaction Other: Questionnaire
MeSH:Burnout, Professional Burnout, Psychological

Primary Outcomes

Description: A questionnaire designed based on the literature review to assess Burnout

Measure: Change in Burnout before COVID-19 and during COVID-19

Time: 1 year before COVID-19 versus during the COVID-19 pandemic (Mrach-June 2020)

Description: A questionnaire designed based on the literature review to assess Job satisfaction

Measure: Change in Job satisfaction before COVID-19 and during COVID-19

Time: 1 year before COVID-19 versus during the COVID-19 pandemic (Mrach-June 2020)

18 Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic

A questionnaire is developed based on the literature and clinical experience. Initial testing will be performed on 20 patients. The first and second sectors include patient demographics and patient clinical diagnosis/scheduled surgery, respectively. The following sectors examine the process of delivering the cancellation/re-scheduling; care after cancellation and whether the procedure conducted elsewhere or not; and the impact of cancellation on patient health, career, and financial aspects.

NCT04433312 Satisfaction, Patient Quality of Life Other: Questionnaire

Primary Outcomes

Description: A questionnaire based on the literature review to access the quality of the life of the patients

Measure: Quality of Life of the patients

Time: During the COVID-19 pandemic 6 months (March-October 2020)

19 Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus

Hospital mortality attributed to SARS-CoV-2 in France increased daily by 28% in the week before confinement. The week following this decision, the daily increase was 30%. During the week of the second week of confinement, it started a decline of 19% estimated over the last 5 days, reaching the cumulative number of 2606 deaths on 29/3 (site https://www.eficiens.com/coronavirus- personal statistics / and calculation). The diagnosis of viral carriage by RT-PCR is reserved for symptomatic cases among caregivers, due to the shortage of available tests and the cumbersome implementation. The carrier diagnosis is the benchmark, on which are implemented the therapeutic strategies and established the national statistics. It can present false negatives, linked to a research too early or too late in relation to the infection, or to a technical defect of the nasal swab sample. Caregivers on the front line in patient care, in hospitals or in the city, have only partial access to this diagnostic test, depending on the existence of symptoms. The implementation of a systematic serological screening, planned by the government and which cannot be based only on the search for the virus, will make it possible to inform the caregivers presenting symptoms or not, of their serological status, and therefore of their degree immunity or, on the contrary, susceptibility to infectious contacts. It should therefore be very voluntarily requested. On the occasion of this screening, the constitution of the COVID-3S cohort will make it possible to verify the degree of contamination in an asymptomatic population, information which is sorely lacking for the estimation of the immune coverage of the population. The implementation of the Covid-3S study will be based on the work of the National Reference Center of Pr B Lina, from the COVID-SER cohort, for the selection of the most efficient test (s). It seems useful to initiate the constitution of this cohort as soon as possible in relation to the evolution of the epidemic. Pending receipt of official recommendations, the lack of knowledge of the performance of serological tests means that it should be applied first to health professionals, better able to appreciate its limits, for the initial period before determining a validated serological screening strategy. Once the strategy has been specified, the gradual expansion of screening to the patient population will provide a more representative basis for the construction of epidemiological models for evaluating strategies.

NCT04441710 COVID Other: Questionnaire
MeSH:Coronavirus Infections

Primary Outcomes

Description: Estimated number of deaths avoided by the various population protection strategies, estimated by applying these strategies to the realistic virtual population.

Measure: Establishment of a reliable prediction model for the effectiveness of virus control

Time: 18 months

20 Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART)

Non-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility. This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .

NCT04456010 COVID19 Fertility Issues ART Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey

Measure: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation

Time: 1 day

Secondary Outcomes

Description: . Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy

Measure: Risk assessment

Time: 1 day

Description: Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey

Measure: Patients'expectations regarding the management of an abrupt closure of the fertility center

Time: 1 day

21 Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic

Impacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic

NCT04463628 Cystic Fibrosis in Children Cystic Fibrosis Behavioral: Questionnaire Behavioral: Interview
MeSH:Cystic Fibrosis Fibrosis

Primary Outcomes

Description: Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical),

Measure: Cancellation or postponement of consultations by the health professional or patient,

Time: Up to 6 months

Description: Number of consultations cancelled by the teleconsultation/replacement patient,

Measure: Patient cancellation of teleconsultations/telecare replacement,

Time: Up to 6 months

Description: Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled)

Measure: Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled),

Time: Up to 6 months

Description: Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration).

Measure: Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration).

Time: Up to 6 months

Secondary Outcomes

Description: Cancellation or postponement by the patient of consultations (medical or paramedical) Patient cancellation of teleconsultations/telecare proposed by the health professional Cancellation or postponement by the patient of hospitalizations (acute or scheduled)

Measure: The reduction of each of the elements of care provision and health care utilization:

Time: Up to 6 months

Description: Intravenous instead of intravenous administration

Measure: The change of modality of administration of antibiotic cures

Time: Up to 6 months

Description: Questionnaire about taking or not taking treatment during confinement

Measure: Compliance

Time: Up to 6 months

Description: Scale 0-21

Measure: Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well)

Time: Up to 6 months

Description: A questionnaire on the presence or absence of toxic consumption

Measure: Presence or absence of toxic consumption (drug, alcohol) during the lockdown

Time: Up to 6 months

Description: Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods)

Measure: Evaluation of the knowledge, experience and social representations of the risk of Covid-19

Time: Up to 6 months

Description: Role of social inequalities in the consequences of containment assessed by qualitative methods

Measure: Assessing the role of social inequalities in the consequences of lockdown

Time: Up to 6 months

Description: Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis

Measure: Suspected and/or confirmed Covid-19 in patients with cystic fibrosis.

Time: Up to 6 months

22 Perceptions of Undergraduate Students and Teaching Staff on Online Teaching and Learning in the Wake of COVID-19 Pandemic in an Egyptian Private University: A Cross-Sectional Study

Spread of COVID-19 in the world has led to a shift in teaching and learning techniques to online methods in order to prevent transmission of the disease. Misr International University (MIU) has an established online learning system that has been used together with face-to-face classes. The aim of this study is to assess and compare the satisfaction and perceptions of full-time teaching staff and undergraduate students regarding online learning during COVID-19 crisis.

NCT04466371 Covid19 Other: Questionnaire

Primary Outcomes

Description: Assess level of satisfaction with online learning using a questionnaire

Measure: Satisfaction with online learning

Time: 1 month

Secondary Outcomes

Description: Assess level of knowledge about COVID-19 using a questionnaire

Measure: Knowledge about COVID-19 crisis

Time: 1 month

Description: Assess level of perception of COVID-19 crisis using a questionnaire

Measure: Perception of COVID-19 crisis

Time: 1 month

23 Assessment of Vision-related Quality of Life (VRQOL) in Cataract Patients During the COVID-19 Pandemic

The aim of this questionnaire survey is to evaluate the improvement in vision-related quality of life before and after cataract surgery using the National Eye Institute Visual Function Questionnaire 25 and the delay of improvement in the COVID-19 pandemic.

NCT04468308 Senile Cataract Other: Questionnaire
MeSH:Cataract
HPO:Cataract Membranous cataract

Primary Outcomes

Description: Extent of improvement of vision-related qualitiy of life due to cataract surgery measured with the National Eye Institut Visual Function Questionnaire 25.

Measure: Improvement Vision-related quality of life

Time: 3 months

Secondary Outcomes

Description: Delay of improvement of vision-related qualitiy of life in the COVID-19 pandemic measured in days between the originally scheduled operation and the actual operation date

Measure: Delay of Vision-related quality of life

Time: 3 months

Description: Visual acuity difference between visual acuity at the time of indication for cataract surgery, on the day of surgery and one month postoperatively.

Measure: Visual acuity

Time: 1 month


Related HPO nodes (Using clinical trials)


HP:0000518: Cataract
Genes 987
BAP1 SDCCAG8 MTAP KCNJ13 KCNAB2 POMT1 ARHGAP31 COX1 PTEN REEP6 RAB3GAP1 KIAA1549 ERCC3 MEFV CLRN1 BRIP1 CRYGD COL2A1 MED25 CRYGD COL2A1 PCYT1A SALL4 YAP1 EYS KCNH1 OPA3 GJA1 ADAMTS18 RDH12 RAB3GAP2 PEX1 GLA WDR35 CC2D2A CCR1 TRNL1 PTCH1 SEC23A GALK1 GJA1 USH1C FAM111A FTL TRNK RNF113A TFAP2A GSR SMCHD1 XRCC4 RPGRIP1 SLC7A14 GNAS KCNH1 PHYH PEX12 SLX4 PEX10 ESCO2 PTCH2 OCLN AGBL5 WRN POMGNT1 BCOR SUFU AGA RAD21 C4A COL2A1 BUB3 CEP290 ERCC2 PAX6 ALDH18A1 RPGRIP1 BEST1 KCNJ13 COL11A1 SALL2 FANCA RET LAMB1 CRYGB TBR1 PEX12 TRAPPC11 CYP1B1 PEX7 BRF1 VIM FAR1 COG4 RAB18 GEMIN4 PHGDH ALDH18A1 GJB6 IQCB1 XRCC2 CRB1 TBC1D20 TMEM67 KRT71 PTPN22 ABHD12 TRAPPC11 OCRL EBP SRD5A3 ERCC2 FAM126A OFD1 ATAD3A TINF2 NPHP1 USH1G ARL6 GTF2IRD1 CLPB UFD1 FANCB CDHR1 FAS UNC45B HNRNPA2B1 WT1 PIGY COL18A1 CEP57 CNGA1 FANCM DHDDS RAB3GAP1 POLG ERCC6 NF2 RNF13 TONSL TRNW EP300 SUMF1 ALX3 B3GALNT2 POMGNT1 NEK2 ITPA POMT1 MAK PHF6 CLIP2 COL4A3 ALX3 ERCC2 BBS2 COMT POMT2 WDPCP FKTN PEX5 PLK4 PEX11B CRPPA SIL1 DNMT1 PEX26 IL23R TULP1 SMAD4 FOXE3 ERCC3 ERAP1 C8ORF37 PEX5 NEU1 NOTCH1 DMPK PTH CEP78 HIRA DKC1 NR2E3 PEX19 AKT1 CERKL CREBBP MMP1 SEC23B FYCO1 DYNC2I2 HBB FKTN CRPPA CC2D2A GSN AKT1 TBC1D24 GJA3 TERT HLA-B RAB18 WNT3 ADAMTS10 PEX2 TRNL1 COL18A1 MAD2L2 DDB2 ARSL IQCB1 ANAPC1 CRYBA4 PRPF4 BCS1L GUCY2D DYNC2H1 FBN1 TUB VSX2 PEX13 SMARCE1 TTC8 KIAA1109 RP9 XYLT2 KMT2A BDNF PTEN MKS1 ARID2 PAH RHO HGSNAT ALX1 ERCC4 FLVCR1 CTC1 DNM1L ND6 KIF1B ARHGEF18 PMM2 KRT6A RP1 GNAS RECQL4 SMAD3 HDAC8 PALB2 ALG2 PEX16 SLC33A1 OTX2 SIX6 ND1 PAH SDHD RP2 PIK3CA DHCR7 RAB3GAP1 OAT CHRDL1 MAF VHL SC5D GBA2 PEX16 NPHP3 FKRP TRAPPC11 SMARCD1 NUP188 ERCC5 RPS6KA3 ALMS1 GUCA1B PDE6G TFAP2A CCDC28B ZNF335 HSF4 B3GLCT PRDM16 ERCC1 COX7B IDH3B MFRP B4GALNT1 POMGNT2 LMNA KRT81 PEX13 GDNF ALDOB RREB1 ALDH18A1 PDE6B PEX11B GJB6 TRNE ZNF408 PEX7 LOXL1 NACC1 FKRP GTF2H5 PEX3 TMEM216 PNPT1 FAM111A HTRA2 PAX6 PEX19 PEX1 SPATA7 FKTN KCNJ13 POMK TONSL RPE65 UBA5 COL4A3 CYTB GNAS IKBKG POMGNT1 DYNC2I1 SMARCB1 MYO7A EED BFSP2 BCOR RPGR FANCD2 LARGE1 NEU1 ERCC5 GNPAT IKBKG POMT1 POLG MAB21L2 PLCG2 DMPK PEX2 TWNK POLG2 DGUOK NAA10 BAZ1B PIK3CA CENPF PTH1R CYP7B1 BCOR POMT2 GMPPB COL4A5 EBP PCDH15 KCTD1 SDHD ACTB GP1BB POMT1 MIP CLPB MIPEP MVK CASK ENTPD1 ARID1B RAD51 GALT NPHP4 JAG1 ZNF408 COL4A4 REEP6 COL9A3 SLC25A4 PEX11B EYS B4GALNT1 SRD5A3 LIG4 CRX RGR ERCC6 ERCC3 MED25 EPG5 PTEN NR2E3 APC PEX5 ESCO2 NAGA ZBTB20 NHS SEC23A FGF5 AIRE AIRE STAT4 KLHL7 B3GALNT2 CBS TCOF1 FH RPGRIP1 AKT1 CEP164 CRYGC ADAMTSL4 ACTB RAD51C CDH23 BTNL2 FOXC2 OAT SDHB BBS2 ERCC2 TBX1 TBC1D24 USH2A GMPPB RP2 SETD5 JAM3 IFT172 KCNA4 BMP4 KIF11 FOXC1 BBS1 NMNAT1 FAM161A CRYGS RPE65 CRYAB PARN EOGT ALDH6A1 SLC40A1 ATP6V1A PEX10 SLC16A12 COL11A1 KDSR FBN1 VCP ARL3 LRAT PEX7 GABRD TGFBI POMT2 PAX6 NACC1 GALT PAX6 WDR19 TDRD7 MERTK P3H2 HLA-DRB1 COL2A1 DPAGT1 COL11A1 POMGNT1 IARS2 COL11A1 FAS CNGB3 WDR19 POMT2 BUB1B FTL HSPG2 CRX C8ORF37 GNAS SUFU CRB1 RD3 LIMK1 MPLKIP FANCL AFF4 PRPF6 IMPG2 WRN AMMECR1 ARL6 CYSLTR2 PEX7 LARGE1 KIF11 IFT140 ELN IL12A-AS1 LSS CEP55 GMPPB RRM2B CRYBA1 ATP6V1B2 WRAP53 TRNC ARL3 GFER ALDH18A1 PNPT1 SALL4 ZNF408 ALG2 PAX6 FKTN TRNK XPC RHOA SOX11 KANSL1 AIPL1 KLRC4 CRYBA2 ERCC8 PEX6 PHGDH AGK TELO2 USH2A BFSP1 COL2A1 POLR1D AGK GJA1 LIPH TMTC3 GNAS POLG GNAQ MYMK DOCK6 LRP2 MYSM1 FLI1 MAN2B1 WFS1 MIR140 PEX1 NOD2 ARVCF DLL4 PITX2 CRX COL9A2 INVS PRUNE1 COL2A1 TRIM44 B9D1 SMCHD1 CRYGC SKI RBP3 COL4A1 CNGB1 SDHC RBPJ ZNF513 SLC25A4 ABHD5 FIBP SCAPER TRNQ B3GLCT IFT140 GMPPB UBE2T RDH12 PXDN CLN3 LMX1B MAF HNRNPDL SMC1A PEX1 ADGRV1 PEX16 SLC2A1 TWNK XYLT2 PEX11B CEP290 VLDLR PEX14 GNA11 PEX5 MYH9 IL12A PEX19 RFC2 ERCC4 INPP5K SIL1 CFAP410 CDH11 FAR1 ADAMTS10 DHX38 GTPBP2 LCA5 GJA1 KIZ PEX12 PAX6 KRT16 CRYAB PRPF8 RAB3GAP2 HMX1 GALK1 MSMO1 CRYAA PMPCA POMK KRT86 PEX6 NHS JMJD1C PEX13 TMEM70 LRP5 GFER TBC1D20 ABCA4 ERCC6 TRNS2 PEX5 FLNA FGF3 BRCA2 RXYLT1 NRL GJA8 GJB4 NSUN2 POLR1C WT1 GJB3 LMNA PROM1 PIK3R1 BAP1 BRCA1 BUB1B CSPP1 KRT25 WDR81 ZEB2 EPG5 IMPDH1 TCTN2 SOX4 CPAMD8 TARS1 POMT2 ALMS1 ETFDH PRCD TGM3 PNPLA6 ATP8A2 STX16 MVK NDP VCAN FOXE3 ARID1A CA4 PIK3C2A RAB3GAP2 POLR3A CPT2 FZD4 BEST1 NR2E3 PTCH2 TBX1 B4GAT1 FBN1 RECQL4 ERCC2 BUB1 CRYAA DAG1 YAP1 PCARE TKFC TRAF3IP1 USP9X SEC24C ALDH18A1 PEX3 MAX MAF SLC2A1 TMEM107 PTCH1 DOCK6 COL7A1 PEX2 CRYBB2 RB1 SLC25A4 POMT1 CLRN1 AHR LRAT ALG8 FKRP OPA1 AMER1 USP45 PAX2 RSPO2 FANCE PHGDH HNRNPA1 SMARCC2 NOP10 IFT80 RFWD3 SPRTN SHROOM4 ZBTB20 FTL RAB3GAP2 CRB1 GCNT2 TMEM127 NIPBL INPP5K NF2 COG4 GTF2H5 RBP3 GMPPB TOPORS PHYH CAV1 NOD2 DSG4 HSPG2 PEX26 CHMP4B PHGDH SCAPER PEX5 ARL2BP TUBG1 CRYBB1 CTDP1 INTS1 MYO7A ARL2BP COL11A1 CRYBB3 PEX10 FANCF ADNP LONP1 PEX26 LEMD2 ITM2B TRIP13 COX3 MIR184 EPHA2 ATOH7 MAN2B1 PRPF3 RAB3GAP2 WHRN FIG4 SMC3 GTF2E2 FAM126A PITX3 CEP290 ALDH18A1 FANCG LRP5 RERE LARGE1 TRNV PDZD7 CA8 KRT74 SALL1 INPP5E CYP27A1 FANCI TWNK NEK9 PEX13 POMGNT1 UBAC2 POLG LMX1B CYP7B1 APC MORC2 CRYBB1 TRIM44 UBE2A EBP ERCC5 FKRP LPAR6 IMPDH1 ANO10 RTEL1 PTEN VHL ABCA12 PEX26 SMARCA4 ALDH18A1 ABHD5 NDP AHI1 RPGRIP1L ETFA SAG NDUFB11 PEX2 CDH23 PLOD3 TLR4 SLC25A13 HLA-A CNBP NDP HARS1 RIC1 FAM111B DPF2 MAF LOXL3 SPATA7 NOTCH2 ARSG WNT3 SLC4A4 DACT1 CRYAB TWNK PEX3 SF3B1 RPE65 ETFB AGK KLLN TUBB2B PEX14 GDF6 SC5D COX2 TRNF GTF2I XPA GNAS IMPDH1 LRP4 DHX38 OCRL IDH3A KCNN3 DHCR7 FKRP KRT83 B9D2 IL10 RHO MIR204 PEX6 NPM1 COL4A1 RP9 COL9A1 PTCH1 LTBP2 IARS2 LARGE1 VPS13A RLBP1 CRYBA4 PQBP1 TKFC VLDLR PAX6 EBP COL7A1 CNBP GJA8 FBN1 AFF4 LIM2 LRP5 BBIP1 TERC NHS TRPV4 RS1 POMK LONP1 KRT17 CYP27A1 TUBGCP6 ND5 CTDP1 ABCA2 FIG4 FANCC FBXL4 PRPH2 ERCC2 ROM1 DAG1 GUCY2D TBL2 CIB2 SDHB MAP2K2 OPA3 PEX14 MAFA HCCS FLNB SEMA4A AP1S1 PEX3 RDH11 TULP1 SNRNP200 IFT88 VAC14 SIPA1L3 ESPN PEX16 GBA2 USF3 OFD1 TULP1 KCTD1 FSCN2 TRNS1 FKTN ELP4 USP9X NHP2 B3GALNT2 TMEM231 PEX16 PEX3 PITX3 IMPG2 PSAT1 SMAD4 TKT FOXC1 USB1 PRPF31 KRT6B ADAMTSL4 DKC1 TRNS2 PDE6A USP8 WDR73 CRYBB2 COL2A1
Protein Mutations 0
SNP 0
HP:0002721: Immunodeficiency
Genes 268
PIK3CA CCDC47 CTBP1 ATRX NHEJ1 BLNK CHD1 CD81 NOP10 IKBKB CD79A TNFRSF13C CD19 AICDA LIG4 CD19 IRF2BP2 LAMTOR2 IFNGR1 UNC119 IGHM TTC7A CD81 PNP SPATA5 RAG2 PKP1 WRAP53 ADA2 TTC37 FGFRL1 CLCA4 TERT RAG1 HYOU1 LAT TYK2 LRBA TTC7A NFE2L2 CD19 DCTN4 RREB1 CD40LG FRAS1 IKBKG TNFRSF13B CFTR RAG1 IRAK4 MAN2B1 CTLA4 JAK3 SHANK3 AGL IL21 ICOS PRKDC TNFRSF13C XRCC4 LIG4 CARD9 BSCL2 TBCE CTPS1 IL7R ANTXR2 MAN2B1 HELLS IL21R MALT1 CD3G LAMTOR2 AP3D1 CD40 ARVCF MBTPS2 ACP5 PTPRC NFKB2 TFRC MS4A1 MAPK1 MTHFD1 LYST ADA POLE RAG2 XIAP SDHC DNMT3B UNG BCL11B DOCK2 ORAI1 RTEL1 IL12RB1 TLR3 FOS AK2 IL2RG TRAF3 CTLA4 DCLRE1C SIN3A SLC46A1 LRRC8A AGPAT2 TINF2 DCLRE1C IRF7 GP1BB TGFB1 UFD1 PPARG LETM1 CAVIN1 ADA ICOS SP110 CD247 IL2RG IRAK4 RAC2 ICOS MMUT TICAM1 KLLN PIK3R1 WIPF1 NFKB1 RBCK1 CORO1A IRF8 STAT1 XRCC4 MEIS2 EPG5 RTEL1 ZBTB24 IKZF1 NSD2 XIAP EXTL3 NCF1 STIM1 FOXN1 MS4A1 GATA2 COG6 CRKL ISG15 COMT RAG1 NPM1 ATM WAS HBB RNF168 RMRP SKIV2L CDCA7 JMJD1C STAT1 CHD1 FOXN1 PRPS1 RAB27A CDC42 UROS BCL10 SKIV2L DKC1 TNFRSF13C DNMT3B FCGR3A HIRA DKC1 ACTB BCR TNFRSF4 ZBTB24 CDH23 SH2D1A CPLX1 CYBA PGM3 CDC42 SEC23B STK4 TBX1 CD3E CD79B CHD7 POLE ACD IGLL1 TERC IFNGR2 TNFRSF13B CD28 UNC93B1 STX1A EPG5 AKT1 TBK1 SMARCAL1 TERT CR2 IRF8 RMRP IL2RG IL12B IL2RB NFKB1 NCF2 RAG2 WHCR PARN RTEL1 SIK3 SDHB LMNB2 PIK3CD CARD11 FCN3 CAV1 TBX1 TCF3 CYBB PIK3R1 CR2 USF3 PTEN MYC TNFSF12 AK2 MAGT1 CR2 IL2RA LCK RNF168 CD3D NHP2 IKBKG SEC24C PARN NFKB2 IL7R TNFSF12 BTK LYST CUL4B USB1 BUB1B PRKCD CTC1 SPATA5 DKC1 STAT1 GATA1 TINF2 USP8 RAG1 PGM3 TNFRSF1B SDHD MYD88
SNP 0
Protein Mutations 0
SNP 0